Symbol
| BNIP3
| contributors: mct/pgu - updated : 15-06-2015
|
HGNC name
| BCL2/adenovirus E1B 19kDa interacting protein 3
|
HGNC id
| 1084
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --low
|  
|
by aberrant DNA methylation of the 5' CpG island and histone deacetylation in haematopoietic tumours | tumoral
|  
|  
| --low
|  
|
in chronic pancreatitis and pancreatic cancer with poorer survival | tumoral
|  
|  
| --low
|  
|
downregulated in primary myelofibrosis | constitutional
|  
|  
| --over
|  
|
in heart failure and contributes to loss of myocardial cells during I/R (ischaemia/reperfusion) | constitutional
|  
|  
| --low
|  
|
was protective against hypoxia-induced autophagy and cell death | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
| |
|
System | Type | Disorder | Pubmed |
neurology | neurodegenerative | | |
. FOXO3 and BNIP3 as potential therapeutic targets in muscle wasting disorders and other degenerative and neoplastic diseases in which autophagy is involved | cancer | | | |
. FOXO3 and BNIP3 as potential therapeutic targets in muscle wasting disorders and other degenerative and neoplastic diseases in which autophagy is involved | cancer | | | |
treatment with Torin1, an MTOR inhibitor, decreased the BNIP3 level and enhanced the death of hypoxic tumor cells |
| | |